tyrosine has been researched along with uk 81,252 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Kaye, B; Macrae, PV; Saunders, KC; Venn, RF | 1 |
| Barnard, G; Kaye, B; Macrae, PV; Saunders, KC; Venn, RF | 1 |
| Hettiarachchi, J; Ramsay, LE; Wallis, EJ | 1 |
| Allen, MJ; Hartford, C; Lee, A; Middlemost, S; Norton, GR; Trifunovic, B; Woodiwiss, AJ | 1 |
| Asher, JR; Naftilan, AJ | 1 |
| Nathisuwan, S; Talbert, RL | 1 |
| Allikmets, K | 1 |
| Maki, T; Nasa, Y; Takahashi, M; Takeo, S; Tanonaka, K | 1 |
| Chang, RK; Shojaei, AH | 1 |
| Juszczak, K; Machowska, A; Novak, P; Thor, P | 1 |
| Caballero, J; Chibale, K; Douglas, RG; Espinoza-Moraga, M; Poblete, H; Sharma, RK; Sturrock, ED | 1 |
| Acharya, KR; Chibale, K; Cozier, GE; Schwager, SL; Sharma, RK; Sturrock, ED | 1 |
| Acharya, KR; Cozier, GE; Sharma, U; Sturrock, ED | 1 |
3 review(s) available for tyrosine and uk 81,252
| Article | Year |
|---|---|
Vasopeptidase inhibition: a new direction in cardiovascular treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Cardiovascular Diseases; Endothelium, Vascular; Humans; Mesylates; Metalloendopeptidases; Natriuretic Peptide, Brain; Protease Inhibitors; Pyridines; Renin-Angiotensin System; Thiazepines; Tyrosine | 2000 |
A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Lisinopril; Mesylates; Natriuretic Peptide, Brain; Neprilysin; Pyridines; Randomized Controlled Trials as Topic; Thiazepines; Tyrosine | 2002 |
The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial Natriuretic Factor; Dose-Response Relationship, Drug; Humans; Hypertension; Mesylates; Protease Inhibitors; Pyridines; Renin-Angiotensin System; Sympathetic Nervous System; Thiazepines; Tyrosine; Vascular Resistance | 2009 |
2 trial(s) available for tyrosine and uk 81,252
| Article | Year |
|---|---|
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Guanosine Monophosphate; Humans; Hypertension; Lisinopril; Male; Mesylates; Middle Aged; Neprilysin; Renin; Tyrosine | 1998 |
Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Blood Pressure; Double-Blind Method; Enzyme Inhibitors; Female; Heart Rate; Hormones; Humans; Hypertension; Lisinopril; Male; Mesylates; Middle Aged; Neprilysin; Tyrosine | 1999 |
9 other study(ies) available for tyrosine and uk 81,252
| Article | Year |
|---|---|
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biological Availability; Endopeptidases; Humans; Kidney; Mass Spectrometry; Mesylates; Methanol; Protease Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Tyrosine | 1998 |
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Topics: Angiotensin-Converting Enzyme Inhibitors; Endopeptidases; Fluoroimmunoassay; Humans; Kidney; Mesylates; Protease Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Tyrosine | 1998 |
Sampatrilat. UK 81252.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drugs, Investigational; Endopeptidases; Humans; Hypertension; Mesylates; Protease Inhibitors; Rats; Rats, Inbred SHR; Tyrosine | 1999 |
Sampatrilat Shire.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Contraindications; Endopeptidases; Heart Failure; Humans; Hypertension; Mesylates; Protease Inhibitors; Structure-Activity Relationship; Tyrosine | 2002 |
Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
Topics: Animals; Chronic Disease; Collagen; Disease Models, Animal; DNA; Enzyme Inhibitors; Fibroblasts; Heart Failure; Hemodynamics; Ligation; Male; Mesylates; Myocardial Infarction; Myocardium; Neprilysin; Organ Size; Peptide Hydrolases; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Tyrosine; Ventricular Remodeling | 2003 |
Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration.
Topics: Absorption; Administration, Oral; Animals; Area Under Curve; Biological Availability; Dogs; Drug Interactions; Emulsions; Excipients; Glycerides; Mesylates; Organic Chemicals; Tyrosine | 2004 |
The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme.
Topics: Angiotensin-Converting Enzyme Inhibitors; Humans; Mesylates; Models, Molecular; Peptidyl-Dipeptidase A; Protease Inhibitors; Protein Domains; Tyrosine | 2016 |
Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity.
Topics: Aspartic Acid; Catalytic Domain; Crystallography, X-Ray; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Mesylates; Peptidyl-Dipeptidase A; Protease Inhibitors; Protein Binding; Protein Conformation; Substrate Specificity; Tyrosine | 2018 |
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Crystallography, X-Ray; Drug Design; Mesylates; Neprilysin; Peptidyl-Dipeptidase A; Protein Binding; Protein Structure, Secondary; Pyridines; Thiazepines; Tyrosine | 2020 |